In the last trading session, 6.95 million shares of the Dyne Therapeutics Inc (NASDAQ:DYN) were traded, and its beta was 1.16. Most recently the company’s share price was $13.82, and it changed around -$0.59 or -4.09% from the last close, which brings the market valuation of the company to $1.57B. DYN currently trades at a discount to its 52-week high of $47.45, offering almost -243.34% off that amount. The share price’s 52-week low was $6.36, which indicates that the current value has risen by an impressive 53.98% since then.
Dyne Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.27. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 7 rate it as Overweight. Among the rest, 1 recommended DYN as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Dyne Therapeutics Inc is expected to report earnings per share of -0.94 for the current quarter.
Dyne Therapeutics Inc (NASDAQ:DYN) trade information
Instantly DYN has showed a red trend with a performance of -4.09% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 15.23 on recent trading dayincreased the stock’s daily price by 9.26%. The company’s shares are currently down -41.34% year-to-date, but still down -4.03% over the last five days. On the other hand, Dyne Therapeutics Inc (NASDAQ:DYN) is 17.72% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $46, which translates to bulls needing to increase their stock price by 69.96% from its current value. Analyst projections state that DYN is forecast to be at a low of $34 and a high of $48.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -59.45%. Dyne Therapeutics Inc earnings are expected to increase by -16.29% in 2025, but the outlook is positive 0.70% per year for the next five years.
DYN Dividends
Dyne Therapeutics Inc’s next quarterly earnings report is expected to be released in July.
FCPM III SERVICES B.V., with 8.4808% or 7.85 million shares worth $276.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
